I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China.
| Revenue (Most Recent Fiscal Year) | $3.89M |
| Net Income (Most Recent Fiscal Year) | $-22.23M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.52 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -19.81% |
| Return on Assets (Trailing 12 Months) | -18.63% |
| Current Ratio (Most Recent Fiscal Quarter) | 22.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 22.35 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.61 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 81.66M |
| Free Float | 63.61M |
| Market Capitalization | $102.89M |
| Average Volume (Last 20 Days) | 0.21M |
| Beta (Past 60 Months) | 1.13 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 38.38% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |